Immunomedics (IMMU) and UCB (UCBJF.PK) tweak their pact for developing and marketing...
Wednesday, December 28, 2011, 3:02 AM ETImmunomedics (IMMU) and UCB (UCBJF.PK) tweak their pact for developing and marketing epratuzumab, a drug for lupus, cancer and other diseases. The changes predominately concern marketing rights. UCB also gets a five-year warrant to buy 1M Immunomedics shares at $8 apiece; IMMU currently at $3.37.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles